@article{5bb87eec3bf647d38f5b28948cb16916,
title = "Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies",
abstract = "Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.",
keywords = "Myelofibrosis, chronic myeloid leukemia, clinical, systemic mastocytosis, thrombosis, translational",
author = "Mughal, {Tariq I.} and Naveen Pemmaraju and Rafael Bejar and Gale, {Robert P.} and Prithviraj Bose and Kiladjian, {Jean Jacques} and Josef Prchal and Daniel Royston and Daniel Pollyea and Peter Valent and Br{\"u}mmendorf, {Tim H.} and Tomasz Skorski and Mrinal Patnaik and Valeria Santini and Pierre Fenaux and Nicole Kucine and Srdan Verstovsek and Ruben Mesa and Tiziano Barbui and Guiseppe Saglio and {Van Etten}, {Richard A.}",
note = "Funding Information: P.B: Consultancy/Scientific Advisory Board: Incyte, BMS, CTI BioPharma, and Kartos; Research funding (to institution): Incyte, BMS, CTI BioPharma, Kartos, Constellation, Blueprint, Astellas, Pfizer, NS Pharma and Promedior. R.B: Stock/Employment: Aptose Biosciences; Data & Safety Monitoring Board Chair: Bristol Myers Squibb, Gilead, Epizyme; Consultant: Bristol Myers Squibb, Takeda, Daiichi‐Sankyo, AbbVie, Astex; Research Funding: Bristol Myers Squibb, Takeda; Data Review Committee: Astex. T.H.B: No relevant disclosures. T.B: No relevant disclosure. P.F: No relevant disclosures. R.P.G: No relevant disclosures. J‐J.K: Scientific Advisory Board: Novartis, Celgene, AOP Orphan. N.K: No relevant disclosures; R.M: Research support from BMS, Incyte, Abbvie, Samus, Genotech, Promedior, and CTI; Consultancy/Scientific Advisory board: Novartis, Sierra Onc, LaJolla, and Pharma. T.I.M: Royalties: Oxford University Press, Informa; Stock/Employment: Stemline; Founder: Alpine Oncology Foundation; Scientific Advisory Board: Inivata. J.P: No relevant disclosures. M.P: Consultancy/Advisory Board: Stemline; research funding: Kura Oncology. N.P: Consultancy/Scientific Advisory Board: Celgene, Stemline, Incyte, Novartis, MustangBio, Roche Diagnostics, LFB and Pacylex; Research funding (to institution): Stemline, Novartis, Abbvie, Samus, Cellectis, Plexxikon, Daiichi‐Sankyo, Affymetrix and SagerStrong Foundation. D.P: Consultancy/Scientific Advisory Board: Abbvie; Research funding: Abbvie. D.R: No relevant disclosures. P.V: Scientific Advisory Board: Pfizer, Novartis, Blueprint, Celgene. T.S.: No relevant disclosures. V.S: No relevant disclosures. G.S: No relevant disclosures. R.V.E: Consultancy: Novartis. S.V: Research funding (to institution): Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp., Genentech, Blueprint Medicines Corp., Novartis, Sierra Oncology, Pharma Essentia, Astra Zeneca, Ital Pharma, Protagonist Therapeutics; Consultancy: Constellation, Pragmatist, Sierra, Incyte, Novartis, Celgene. Publisher Copyright: {\textcopyright} 2022 John Wiley & Sons Ltd.",
year = "2022",
month = oct,
doi = "10.1002/hon.2987",
language = "English (US)",
volume = "40",
pages = "491--504",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "4",
}